SNU-16 Cell Line

Brief Introduction
Product List

General Information
Organism	Homo sapiens, human
Cell Line Description	SNU-16 is a human gastric adenocarcinoma cell line established from malignant ascites collected before chemotherapy from a 33-year-old female patient with poorly differentiated stomach carcinoma. The cells grow in suspension as multicellular aggregates and combine an FGFR2-amplified signaling background with c-MYC amplification, defined TP53 and RHOA variants, a CD44–SLC1A2 fusion, and microsatellite stability. This profile supports gastric cancer signaling, targeted-inhibitor, apoptosis, resistance, three-dimensional aggregate, biomarker, and xenograft studies. Its metastatic-fluid origin and aggregate growth require density-controlled handling and careful assay normalization.
Cell Type	Human gastric adenocarcinoma epithelial cell
Tissue	Stomach
Sampling Site	Malignant ascites; metastatic-site specimen
Disease	Gastric adenocarcinoma, historically described as poorly differentiated gastric carcinoma
Differentiation	Poorly differentiated
Year Established	1987
Gender	Female
Age	33 years
Population Background	Korean, East Asian
Morphology	Epithelial morphology with multicellular aggregate formation
Growth Mode	Suspension growth, predominantly as multicellular aggregates
Applications	1. Poorly differentiated gastric adenocarcinoma biology 2. Metastatic gastric cancer and malignant-ascites research 3. FGFR2 amplification and pathway-dependency studies 4. FGFR, ERBB3, FRS2, ERK, and AKT signaling assays 5. Targeted-inhibitor sensitivity and resistance studies 6. Apoptosis, proliferation, and survival assays 7. c-MYC amplification research 8. TP53, RHOA, MSH6, and DNA-repair studies 9. CD44–SLC1A2 fusion research 10. CEA, TAG-72, VIP-receptor, and gastric biomarker studies 11. Suspension aggregate and three-dimensional culture assays 12. Semisolid colony-formation assays 13. Xenograft efficacy and pharmacodynamic studies 14. CRISPR, RNA interference, and gene-expression studies
Characteristics
FGFR2 Amplification	FGFR2 is amplified and overexpressed, producing constitutive receptor phosphorylation and a strong pathway-dependent growth phenotype
c-MYC Status	c-MYC is amplified. The original characterization did not detect amplification or rearrangement of N-MYC, L-MYC, MYB, or EGFR.
ERBB2 Context	ERBB2 RNA is expressed, but the original characterization described levels comparable to other gastric cancer cell lines rather than a uniquely high-amplification state
TP53 Variant	TP53 c.614A>T, producing p.Tyr205Phe
RHOA Variants	RHOA c.13C>T (p.Arg5Trp) and c.117T>G (p.Phe39Leu), each recorded as heterozygous
MSH6 Variant	MSH6 c.4065_4066insTTGA, producing p.Lys1358fs*2; recorded as heterozygous
Microsatellite Status	Microsatellite stable despite the heterozygous MSH6 frameshift variant; do not infer mismatch-repair deficiency from the variant alone
Gene Fusion	CD44–SLC1A2 fusion
Surface and Secreted Markers	Expresses carcinoembryonic antigen and TAG-72 surface glycoproteins; blood-group phenotype is A, Rh-positive
Neuroendocrine-Related Features	Vasoactive intestinal peptide receptors and L-dopa decarboxylase are present, whereas gastrin receptors were not detected in the original characterization
Tumorigenicity	Tumorigenic and suitable for FGFR2-amplified gastric cancer xenograft studies
Karyotype	Bimodal, hypotetraploid chromosome distribution with three normal X chromosomes per cell, recurrent structural markers, double minutes in most cells, and approximately 1% higher-ploidy cells
Culture Conditions and Handling
Culture Conditions	37°C in a humidified atmosphere containing 5% CO₂
Culture Surface	Standard tissue-culture flasks; attachment coating is not required for routine suspension propagation
Growth Appearance	Free-floating single cells and multicellular aggregates; moderate aggregation is an expected feature of healthy cultures
Medium Renewal	Add fresh medium every 3–4 days according to cell density. Complete or partial medium replacement can also be performed after gentle centrifugation and resuspension.
Routine Maintenance	Maintain cultures by adding fresh complete medium as density increases. For more complete medium exchange, collect the suspension, centrifuge gently, remove spent medium, and resuspend the cells in fresh complete medium.
Aggregate Management	Mix gently but thoroughly before sampling or splitting. If a single-cell suspension is required, dissociate aggregates using a validated mechanical or enzymatic method and confirm viability; avoid excessive shear that can distort response assays.
Subculturing	1. Examine aggregate size, density, medium color, and viability. 2. Gently resuspend the culture to distribute aggregates evenly. 3. Transfer the required fraction into a sterile centrifuge tube when complete medium replacement is needed. 4. Centrifuge using a validated low-speed setting and remove spent medium without disturbing the pellet. 5. Resuspend gently in pre-warmed RPMI-1640 with 10% fetal bovine serum. 6. Seed fresh flasks at a density that maintains logarithmic growth and avoids prolonged crowding. 7. Return cultures to 37°C and 5% CO₂ and confirm recovery and expected aggregate formation.
Cryopreservation Medium	Complete growth medium supplemented with 5% DMSO
Cryopreservation	Collect an actively growing culture, prepare a uniform viable-cell suspension, resuspend in chilled cryopreservation medium, dispense into labeled cryovials, cool slowly at a controlled rate, and transfer to long-term storage.
Long-Term Storage	Below −130°C, preferably in the vapor phase of liquid nitrogen
Thawing	Thaw rapidly at 37°C, disinfect the vial exterior, dilute the contents with pre-warmed complete medium, centrifuge at approximately 125 × g for 5–7 minutes, remove residual cryoprotectant, and resuspend in complete medium. Seed promptly and minimize alkaline exposure during recovery.
Biosafety	Handle as human-derived research material under Biosafety Level 1 or the locally assigned equivalent, using appropriate aseptic technique, personal protective equipment, decontamination, and waste procedures.
Handling Notes	Record passage number, viable-cell density, aggregate-dissociation method, medium and serum lot, feeding schedule, and time after seeding.

Cat.No.	Product Name	Price
CSC-RO0169	Cas9 Stable Cell Line - SNU-16	Inquiry

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.

Quick Inquiry